| Literature DB >> 30948417 |
Jo-Hsuan Wu1, Jih-Shuin Jerng2, Chien-Chia Su3.
Abstract
Carteolol, a non-selective beta-antagonist with a potential risk of severe bronchial constriction in patients with asthma, is one of the most commonly prescribed medication for managing ocular pressure in glaucoma. We present a case of a 24-year-old woman with a history of atopy but no known asthma who presented an insidious onset of clinical manifestations compatible with drug-induced asthma after the initiation of carteolol for ocular hypertension control. The patient developed progressive chest tightness and dyspnoea for 2 months before the pulmonary function test revealed a positive bronchoprovocation response. She reported significant improvement of respiratory symptoms within 2 weeks after the discontinuation of carteolol, and a negative provocation response was later confirmed by repeat pulmonary function test. In conclusion, eye drops with non-selective beta-antagonising effect can induce asthmatic symptoms in patients without a previous diagnosis of asthma and should be administered with caution in patients with associated risk factors. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: asthma; contraindications and precautions; drugs: respiratory system; glaucoma; unwanted effects/adverse reactions
Mesh:
Substances:
Year: 2019 PMID: 30948417 PMCID: PMC6453396 DOI: 10.1136/bcr-2019-229343
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X